Compugen Announces Initial Validation of Additional B7/CD28 Protein Family Based Product Candidate

Compugen Ltd. CGEN announced today in vitro validation of a second product candidate based on Compugen-discovered novel members of the B7/CD28 co-stimulatory protein family. Proteins belonging to the B7/CD28 family are of high industry interest in view of their key roles in regulating immune response and are viewed as having significant therapeutic potential in multiple areas of important medical need, including autoimmune diseases, transplantation and cancer.